PortfoliosLab logoPortfoliosLab logo
Boundless Bio, Inc (BOLD)
Performance
Return for Risk
Dividends
Drawdowns
Volatility
Financials

Company Info

ISIN
US10170A1007
IPO Date
Mar 28, 2024

Highlights

Market Cap
$24.60M
Enterprise Value
$58.93M
EPS (TTM)
-$2.60
Gross Profit (TTM)
-$627.00K
EBITDA (TTM)
-$59.95M
Year Range
$0.96 - $1.78
ROA (TTM)
-37.05%
ROE (TTM)
-58.99%

Share Price Chart


Loading graphics...

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Boundless Bio, Inc

Often compared with BOLD:
BOLD vs. IBIT

Performance

Performance Chart

The chart shows the growth of an initial investment of $10,000 in Boundless Bio, Inc, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.


Loading graphics...

S&P 500 Index

Returns By Period

Boundless Bio, Inc (BOLD) has returned -8.33% so far this year and -27.15% over the past 12 months.


Boundless Bio, Inc

1D
1.38%
1M
-5.17%
YTD
-8.33%
6M
-10.57%
1Y
-27.15%
3Y*
5Y*
10Y*

Benchmark (S&P 500 Index)

1D
2.91%
1M
-5.09%
YTD
-4.63%
6M
-2.39%
1Y
16.33%
3Y*
16.69%
5Y*
10.18%
10Y*
12.16%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Monthly Returns

Based on dividend-adjusted daily data since Mar 28, 2024, BOLD's average daily return is -0.39%, while the average monthly return is -8.22%.

Historically, 29% of months were positive and 71% were negative. The best month was Jul 2025 with a return of +17.3%, while the worst month was Jun 2024 at -57.6%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 8 months.

On a daily basis, BOLD closed higher 41% of trading days. The best single day was Sep 19, 2024 with a return of +23.1%, while the worst single day was Jun 25, 2024 at -18.1%.


JanFebMarAprMayJunJulAugSepOctNovDecTotal
2026-3.33%0.00%-5.17%-8.33%
2025-21.03%-15.72%-21.76%16.56%-37.50%-8.18%17.33%-5.49%9.82%13.82%-16.43%2.56%-58.62%
2024-30.53%-7.88%-57.57%-0.52%-5.97%-4.14%-15.85%-6.51%6.23%-79.65%

Benchmark Metrics

Boundless Bio, Inc has an annualized alpha of -68.01%, beta of 1.20, and R² of 0.07 versus S&P 500 Index. Calculated based on daily prices since April 01, 2024.

  • This stock participated in 251.44% of S&P 500 Index downside but only -181.74% of its upside — more exposed to losses than it benefited from rallies.
  • R² of 0.07 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

Alpha
-68.01%
Beta
1.20
0.07
Upside Capture
-181.74%
Downside Capture
251.44%

Return for Risk

Risk / Return Rank

BOLD ranks 21 for risk / return — below 21% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.


BOLD Risk / Return Rank: 2121
Overall Rank
BOLD Sharpe Ratio Rank: 1919
Sharpe Ratio Rank
BOLD Sortino Ratio Rank: 2020
Sortino Ratio Rank
BOLD Omega Ratio Rank: 2121
Omega Ratio Rank
BOLD Calmar Ratio Rank: 1919
Calmar Ratio Rank
BOLD Martin Ratio Rank: 2626
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

Return / Risk — by metrics

The table below present risk-adjusted performance metrics for Boundless Bio, Inc (BOLD) and compare them to a chosen benchmark (S&P 500 Index).


BOLDBenchmarkDifference

Sharpe ratio

Return per unit of total volatility

-0.49

0.90

-1.38

Sortino ratio

Return per unit of downside risk

-0.42

1.39

-1.81

Omega ratio

Gain probability vs. loss probability

0.95

1.21

-0.26

Calmar ratio

Return relative to maximum drawdown

-0.63

1.40

-2.02

Martin ratio

Return relative to average drawdown

-0.86

6.61

-7.47

Explore BOLD risk-adjusted metrics in detail

Dive deeper into individual metrics with historical trends, benchmark comparisons, and performance across different time periods.

Dividends

Dividend History


Boundless Bio, Inc doesn't pay dividends

Drawdowns

Drawdowns Chart

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.


Loading graphics...

Worst Drawdowns

The table below displays the maximum drawdowns of the Boundless Bio, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Boundless Bio, Inc was 92.91%, occurring on Jun 27, 2025. The portfolio has not yet recovered.

The current Boundless Bio, Inc drawdown is 92.28%.


Depth

Start

To Bottom

Bottom

To Recover

End

Total

-92.91%Apr 1, 2024312Jun 27, 2025

Volatility

Volatility Chart

The chart below shows the rolling one-month volatility.


Loading graphics...

Financials

Financial Performance

The chart below illustrates the trends in the financial health of Boundless Bio, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.


Annual
Quarterly

0.0

Valuation

The Valuation section provides an overview of how Boundless Bio, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.


PB Ratio

The chart illustrates the Price-to-Book (P/B) ratio for BOLD in comparison with other companies in the Biotechnology industry. Currently, BOLD has a P/B value of 0.2. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.

Income Statement



TTM
Revenue

Total Revenue

Cost Of Revenue

Gross Profit

Operating Expenses

Selling, General & Admin Expenses

R&D Expenses

Depreciation And Amortization

Total Operating Expenses

Income

Income Before Tax

Operating Income

EBITDA

EBIT

Earnings From Continuing Operations

Net Income

Income Tax Expense

Other Non-Operating Income (Expenses)

Extraordinary Items

Discontinued Operations

Effect Of Accounting Charges

Non Recurring

Minority Interest

Other Items

Interest Income

Interest Expense

Net Interest Income

Values in undefined except per share items